Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...

Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...